论文部分内容阅读
目的探讨影响亚临床型生殖器疱疹患者机体免疫水平的相关因素,以及予免疫调节剂治疗后机体免疫状态的改善情况。方法用荧光定量PCR检测患者带毒情况,用流式细胞仪检测患者的免疫功能。比较带毒阳性组与带毒阴性组,频发组(复发≥6次/年)与少发组(复发<6次/年)以及使用免疫调节剂治疗前后患者的外周血淋巴细胞百分比。结果带毒阳性组CD3~+,CD4~+,CD4~+/CD8~+T细胞均低于带毒阴性组,差异有统计学意义(P<0.05),频发组CD3~+,CD4~+,CD4~+/CD8~+,NK细胞均低于少发组,CD8~+T细胞高于少发组,差异有统计学意义(P<0.05),治疗组CD3~+,CD4~+,CD4~+/CD8~+,NK细胞均低于对照组,CD8~+T细胞高于对照组,差异有统计学意义(P<0.05),治疗后CD3~+,CD4~+,CD4~+/CD8~+,NK细胞均高于治疗前,CD8~+T细胞低于治疗前,差异有统计学意义(P<0.05),在各种分组情况下比较B细胞数值变化,差异无统计学意义(P>0.05)。结论亚临床型GH患者存在免疫功能低下的情况,带毒及频发患者的免疫抑制更为严重,而给予联合应用免疫调节剂后免疫低下较前改善。
Objective To investigate the related factors affecting the immunity of subclinical genital herpes and the improvement of immune status after immunomodulatory agent treatment. Methods Fluorescent quantitative PCR was used to detect the patients’ infection, and the immune function of patients was detected by flow cytometry. The percentage of peripheral blood lymphocytes in patients who were infected with positive group and those with negative drug, frequency of recurrence (≥ 6 times / year) and those of less frequent (recurrent <6 times / year) and before and after treatment with immunomodulatory agent were compared. Results CD3 ~ +, CD4 ~ +, CD4 ~ + / CD8 ~ + T cells were lower in the positive group than those in the negative group (P <0.05) (P <0.05). The levels of CD3 ~ +, CD4 ~ +, CD4 ~ + / CD8 ~ + and NK cells in the treatment group were lower than those in the less developed group and CD8 + T cells in the treated group were higher than those in the less developed group , CD4 ~ + / CD8 ~ +, NK cells were lower than the control group, CD8 ~ + T cells higher than the control group, the difference was statistically significant (P < + / CD8 +, NK cells were higher than before treatment, CD8 ~ + T cells lower than before treatment, the difference was statistically significant (P <0.05), in various groups compared B cell number changes, the difference was not statistically Significance (P> 0.05). Conclusions Immunocompromised patients with subclinical GH are experiencing more severe immunosuppression in patients with poisoning and frequently-occurring disease. However, immunosuppression is improved in combination with immunomodulatory agents.